Tocqueville Asset Management L.P. Has $52.54 Million Stock Position in Johnson & Johnson $JNJ

Tocqueville Asset Management L.P. lowered its position in Johnson & Johnson (NYSE:JNJ) by 1.5% in the third quarter, Holdings Channel.com reports. The fund owned 283,337 shares of the company’s stock after selling 4,387 shares during the period. Johnson & Johnson makes up 0.8% of Tocqueville Asset Management L.P.’s investment portfolio, making the stock its 25th largest holding. Tocqueville Asset Management L.P.’s holdings in Johnson & Johnson were worth $52,536,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson in the third quarter worth $26,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at $28,000. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $27,000. Semmax Financial Advisors Inc. raised its stake in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. Finally, Compass Financial Services Inc lifted its holdings in shares of Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after acquiring an additional 198 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 30,142 shares of company stock valued at $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval for the TECNIS PureSee intraocular lens — a new premium cataract IOL that expands J&J’s surgical portfolio and could help near‑term revenue and margin mix in vision care. Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens
• Positive Sentiment: Citigroup raises its price target to $274 and sets a Buy rating — a notable upside revision that suggests Street analysts see more earnings/pipeline upside, which can attract buy interest. Johnson & Johnson (NYSE:JNJ) Stock Price Expected to Rise, Citigroup Analyst Says
• Positive Sentiment: BofA lifted its price target (to $253) citing pipeline growth — another institutional nod that supports a higher fair value and reassures investors on forward revenue. BofA Raises Johnson & Johnson (JNJ) Price Target on Pipeline Growth
• Positive Sentiment: JNJ seeks EMA label expansion for Tecvayli in multiple myeloma — regulatory progress on high‑value oncology assets supports longer‑term revenue and valuation upside. JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
• Positive Sentiment: Investor lists and dividend articles (Dividend Kings / Best Dividend Stocks) continue to highlight J&J’s defensive yield and dividend reliability, supporting demand from income‑focused investors. The 5 Safest Dividend Kings Are the Only Stocks to Buy Now
• Neutral Sentiment: Barclays reaffirmed its Hold rating — keeps some analyst distribution around a cautious stance despite other upgrades. Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: Analyst notes and valuation updates show modest revisions to fair value as Street remodels pipeline product by product — directionally supportive but not uniformly bullish. How The Johnson & Johnson (JNJ) Narrative Is Shifting With Pipeline Rethinks And New Valuation Targets

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Bank of America reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 2nd. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Leerink Partners raised their target price on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company boosted their price target on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.91.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $1.78 on Friday, reaching $243.82. The stock had a trading volume of 1,938,400 shares, compared to its average volume of 9,012,237. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $587.59 billion, a P/E ratio of 22.05, a price-to-earnings-growth ratio of 2.40 and a beta of 0.34. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71. The stock has a fifty day moving average price of $231.22 and a 200-day moving average price of $205.79.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion during the quarter. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.